Samsung Biologics (KRX:207940) extended its partnership with LigaChem Biosciences to provide antibody-drug conjugate (ADC) services at its new ADC facility, the South Korean biotechnology firm said Thursday.
The collaboration focuses on ADC programs for solid tumor treatments. Samsung's facility, equipped with a 500-liter reactor, offers end-to-end ADC services from development to conjugation, using its expertise in large-scale antibody manufacturing, it said.
Shares of Samsung Biologics rose nearly 1% in recent trade on Friday.